159 related articles for article (PubMed ID: 34834551)
1. Bioinformatics Analysis Identifies Precision Treatment with Paclitaxel for Hepatocellular Carcinoma Patients Harboring Mutant
Lin JC; Liu TP; Andriani V; Athoillah M; Wang CY; Yang PM
J Pers Med; 2021 Nov; 11(11):. PubMed ID: 34834551
[TBL] [Abstract][Full Text] [Related]
2. Integrative analysis of aberrant Wnt signaling in hepatitis B virus-related hepatocellular carcinoma.
Ding SL; Yang ZW; Wang J; Zhang XL; Chen XM; Lu FM
World J Gastroenterol; 2015 May; 21(20):6317-28. PubMed ID: 26034368
[TBL] [Abstract][Full Text] [Related]
3. A precise prognostic signature in CTNNB1-mutant hepatocellular carcinoma: Prognosis prediction and precision treatment exploration.
Wang J; Zhu G
Heliyon; 2023 Dec; 9(12):e22382. PubMed ID: 38125518
[TBL] [Abstract][Full Text] [Related]
4. Mutations in TP53, CTNNB1 and PIK3CA genes in hepatocellular carcinoma associated with hepatitis B and hepatitis C virus infections.
Tornesello ML; Buonaguro L; Tatangelo F; Botti G; Izzo F; Buonaguro FM
Genomics; 2013 Aug; 102(2):74-83. PubMed ID: 23583669
[TBL] [Abstract][Full Text] [Related]
5. Computational analysis of TP53 vs. CTNNB1 mutations in hepatocellular carcinoma suggests distinct cancer subtypes with differential gene expression profiles and chromatin states.
Biterge Süt B
Comput Biol Chem; 2020 Dec; 89():107404. PubMed ID: 33096424
[TBL] [Abstract][Full Text] [Related]
6. Dynamics and predicted drug response of a gene network linking dedifferentiation with beta-catenin dysfunction in hepatocellular carcinoma.
Gérard C; Di-Luoffo M; Gonay L; Caruso S; Couchy G; Loriot A; Castven D; Tao J; Konobrocka K; Cordi S; Monga SP; Hanert E; Marquardt JU; Zucman-Rossi J; Lemaigre FP
J Hepatol; 2019 Aug; 71(2):323-332. PubMed ID: 30953666
[TBL] [Abstract][Full Text] [Related]
7. Liver cancer with concomitant TP53 and CTNNB1 mutations: a case report.
Friemel J; Rechsteiner M; Bawohl M; Frick L; Müllhaupt B; Lesurtel M; Weber A
BMC Clin Pathol; 2016; 16():7. PubMed ID: 27252594
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of PICT1 in patients of hepatocellular carcinoma with wild-type TP53.
Ishibashi M; Kogo R; Shibata K; Ueo H; Uchi R; Matsumura T; Takano Y; Sawada G; Takahashi Y; Mima K; Kurashige J; Akiyoshi S; Iwaya T; Eguchi H; Sudo T; Sugimachi K; Suzuki A; Wakabayashi G; Mori M; Mimori K
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S537-44. PubMed ID: 23532381
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis B virus-associated hepatocellular carcinoma from India: role of viral genotype and mutations in CTNNB1 (beta-catenin) and TP53 genes.
Vivekanandan P; Torbenson M; Ramakrishna B
J Gastrointest Cancer; 2011 Mar; 42(1):20-5. PubMed ID: 20963515
[TBL] [Abstract][Full Text] [Related]
10. TTK Inhibitors as a Targeted Therapy for
Zaman GJR; de Roos JADM; Libouban MAA; Prinsen MBW; de Man J; Buijsman RC; Uitdehaag JCM
Mol Cancer Ther; 2017 Nov; 16(11):2609-2617. PubMed ID: 28751540
[TBL] [Abstract][Full Text] [Related]
11. Targeted genomic profiling identifies frequent deleterious mutations in FAT4 and TP53 genes in HBV-associated hepatocellular carcinoma.
Huang FY; Wong DK; Tsui VW; Seto WK; Mak LY; Cheung TT; Lai KK; Yuen MF
BMC Cancer; 2019 Aug; 19(1):789. PubMed ID: 31395065
[TBL] [Abstract][Full Text] [Related]
12. CTNNB1 mutation suppresses infiltration of immune cells in hepatocellular carcinoma through miRNA-mediated regulation of chemokine expression.
Xiao X; Mo H; Tu K
Int Immunopharmacol; 2020 Dec; 89(Pt A):107043. PubMed ID: 33039961
[TBL] [Abstract][Full Text] [Related]
13. Modeling a human hepatocellular carcinoma subset in mice through coexpression of met and point-mutant β-catenin.
Tao J; Xu E; Zhao Y; Singh S; Li X; Couchy G; Chen X; Zucman-Rossi J; Chikina M; Monga SP
Hepatology; 2016 Nov; 64(5):1587-1605. PubMed ID: 27097116
[TBL] [Abstract][Full Text] [Related]
14. Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.
Lachenmayer A; Alsinet C; Savic R; Cabellos L; Toffanin S; Hoshida Y; Villanueva A; Minguez B; Newell P; Tsai HW; Barretina J; Thung S; Ward SC; Bruix J; Mazzaferro V; Schwartz M; Friedman SL; Llovet JM
Clin Cancer Res; 2012 Sep; 18(18):4997-5007. PubMed ID: 22811581
[TBL] [Abstract][Full Text] [Related]
15. PIN1 in hepatocellular carcinoma is associated with TP53 gene status.
Bae JS; Noh SJ; Kim KM; Jang KY; Park HS; Chung MJ; Park BH; Moon WS
Oncol Rep; 2016 Oct; 36(4):2405-11. PubMed ID: 27499097
[TBL] [Abstract][Full Text] [Related]
16. Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification.
Calderaro J; Couchy G; Imbeaud S; Amaddeo G; Letouzé E; Blanc JF; Laurent C; Hajji Y; Azoulay D; Bioulac-Sage P; Nault JC; Zucman-Rossi J
J Hepatol; 2017 Oct; 67(4):727-738. PubMed ID: 28532995
[TBL] [Abstract][Full Text] [Related]
17. Accumulation of Molecular Aberrations Distinctive to Hepatocellular Carcinoma Progression.
Midorikawa Y; Yamamoto S; Tatsuno K; Renard-Guillet C; Tsuji S; Hayashi A; Ueda H; Fukuda S; Fujita T; Katoh H; Ishikawa S; Covington KR; Creighton CJ; Sugitani M; Wheeler DA; Shibata T; Nagae G; Takayama T; Aburatani H
Cancer Res; 2020 Sep; 80(18):3810-3819. PubMed ID: 32641413
[TBL] [Abstract][Full Text] [Related]
18. Point mutation screening of tumor neoantigens and peptide-induced specific cytotoxic T lymphocytes using The Cancer Genome Atlas database.
Wu W; Chen Y; Huang L; Li W; Tao C; Shen H
Oncol Lett; 2020 Nov; 20(5):123. PubMed ID: 32934692
[TBL] [Abstract][Full Text] [Related]
19. MiR-214 targets β-catenin pathway to suppress invasion, stem-like traits and recurrence of human hepatocellular carcinoma.
Xia H; Ooi LL; Hui KM
PLoS One; 2012; 7(9):e44206. PubMed ID: 22962603
[TBL] [Abstract][Full Text] [Related]
20. Genomic Analysis Revealed New Oncogenic Signatures in
Kancherla V; Abdullazade S; Matter MS; Lanzafame M; Quagliata L; Roma G; Hoshida Y; Terracciano LM; Ng CKY; Piscuoglio S
Front Genet; 2018; 9():2. PubMed ID: 29456550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
